Clinical Trials Logo
  1. Home
  2. Cancer of Breast
  3. NCT02642094

Aging Mammary Stem Cells and Breast Cancer Prevention

Cancer of Breast Clinical Trial

Official title:
Aging Mammary Stem Cells and Breast Cancer Prevention

Clinical Trial Summary

To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens

Clinical Trial Description

A non-randomized, open-label, phase II, window of opportunity trial will be carried out to see if a 5-7 day rapamycin treatment can reduce malignant markers and aberrant MaSC number ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02642094
Study type Interventional
Source The University of Texas Health Science Center at San Antonio
Contact
Status Terminated
Phase Phase 2
Start date July 2016
Completion date May 1, 2022
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT03285607 - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Phase 1
Completed NCT02225470 - Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase 3
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Completed NCT01271738 - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT01980823 - Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Early Phase 1
Completed NCT02658708 - Bright Light on Fatigue in Women Being Treated for Breast Cancer Phase 1
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Completed NCT05584644 - A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03084536 - PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery Phase 2
Terminated NCT02907918 - Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer Phase 2
Completed NCT03007979 - Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Terminated NCT02462200 - Shave Margins in Breast Conservation Therapy Phase 2
Completed NCT03592121 - Study to Investigate the Effect of AB-101 in Breast Cancer Survivors Early Phase 1
Active, not recruiting NCT04855552 - Telehealth Weight Loss Program for Breast Cancer Survivors N/A
Active, not recruiting NCT05364450 - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors N/A
Completed NCT03494400 - Aerobic Training in Treatment for Breast Cancer N/A
Terminated NCT02375048 - Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI Phase 2
Recruiting NCT02476786 - Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Phase 2